Nanobiotix (NASDAQ:NBTX) Shares Gap Up – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares gapped up prior to trading on Wednesday . The stock had previously closed at $39.29, but opened at $41.40. Nanobiotix shares last traded at $41.7010, with a volume of 4,551 shares changing hands.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Leerink Partners lifted their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Nanobiotix presently has an average rating of “Moderate Buy” and a consensus price target of $37.33.

Nanobiotix Trading Up 2.9%

The stock has a fifty day moving average of $39.41 and a 200-day moving average of $36.40.

Institutional Investors Weigh In On Nanobiotix

Several institutional investors have recently modified their holdings of NBTX. Millennium Management LLC purchased a new position in shares of Nanobiotix during the fourth quarter valued at approximately $390,000. Marshall Wace LLP purchased a new position in Nanobiotix during the fourth quarter worth about $220,000. Finally, Royal Bank of Canada grew its holdings in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.